Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
Laura E. Targownik, Eric I. Benchimol, Çharles N. Bernstein, et al.
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. 10, pp. 1354-1363
Closed Access | Times Cited: 51

Showing 26-50 of 51 citing articles:

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
Léa Sequier, Bénédicte Caron, Damien Lœuille, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 6, pp. 686-700
Closed Access | Times Cited: 2
Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?
Carla J. Gargallo-Puyuelo, Viviana Laredo, Fernando Gomollón
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 17
Methotrexate in inflammatory bowel disease: A primer for gastroenterologists
Turki AlAmeel, Eman Al Sulais, Tim Raine
Saudi Journal of Gastroenterology (2022) Vol. 28, Iss. 4, pp. 250-260
Open Access | Times Cited: 11
New Baitouweng decoction combined with fecal microbiota transplantation alleviates DSS-induced colitis in rats by regulating gut microbiota metabolic homeostasis and the STAT3/NF-κB signaling pathway
Xin Gu, Zhiwei Miao, Yantian Wang, et al.
BMC Complementary Medicine and Therapies (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2452-2452
Open Access | Times Cited: 6
Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications
A. Cassinotti, Alberto Batticciotto, Marco Parravicini, et al.
Therapeutic Advances in Gastroenterology (2022) Vol. 15
Open Access | Times Cited: 10
Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – Data from the multicenter CEDATA-GPGE registry study
M. Classen, Jan de Laffolie, Martin Claßen, et al.
Frontiers in Pediatrics (2022) Vol. 10
Open Access | Times Cited: 10
Immunomodulators: still having a role?
Jeffery M. Venner, Çharles N. Bernstein
Gastroenterology report (2022) Vol. 10
Open Access | Times Cited: 10
The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape
Sanjay K. Murthy, Adam V. Weizman, M Ellen Kuenzig, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 6, Iss. Supplement_2, pp. S97-S110
Open Access | Times Cited: 5
TNF-α–Induced miR-21-3p Promotes Intestinal Barrier Dysfunction by Inhibiting MTDH Expression
Zhifeng Jiang, Feiyu Yang, Jingbo Qie, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 10
The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab
Pilar Navajas Hernández, Pilar del Pino Bellido, Laura Lorenzo González, et al.
Revista Española de Enfermedades Digestivas (2023)
Open Access | Times Cited: 3
Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review
Anat Yerushalmy‐Feler, Caroline Brauner, Shlomi Cohen
Pediatric Drugs (2023) Vol. 25, Iss. 5, pp. 489-498
Closed Access | Times Cited: 3
Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus
Yago González‐Lama, Elena Ricart, Daniel Carpio, et al.
BMJ Open Gastroenterology (2024) Vol. 11, Iss. 1, pp. e001246-e001246
Open Access
6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy
Natalie Yu, Tanya Lee, Daniel Tassone, et al.
Internal Medicine Journal (2024)
Closed Access
Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review)
Tsviatko Alexandrov, B. A. Vykova
Koloproktologia (2024) Vol. 23, Iss. 2, pp. 173-183
Open Access
Bile acid metabolism modulates intestinal immunity involved in ulcerative colitis progression
Hua Huang, Shuai Yan, Tianwei Guo, et al.
Heliyon (2024) Vol. 10, Iss. 14, pp. e34352-e34352
Open Access
Ulva lactuca polysaccharides combined with fecal microbiota transplantation ameliorated dextran sodium sulfate‐induced colitis in C57BL/6J mice
Zhengqi Liu, Menghui Wang, Yuanyuan Hu, et al.
Journal of the Science of Food and Agriculture (2024)
Closed Access
Efficacy of infliximab in treatment-naïve patients with stricturing small bowel Crohn’s disease
Bingxia Chen, Zemin Han, Qian Zhou, et al.
Scandinavian Journal of Gastroenterology (2021) Vol. 56, Iss. 7, pp. 812-819
Closed Access | Times Cited: 4
Immunomodulator and Biologic Combination Therapy in IBD: The Debate That Just Won’t Go Away?
Tim Raine, Nicholas A. Kennedy
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. 10, pp. 1343-1344
Closed Access | Times Cited: 3
Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases
Siddharth Singh, Herbert C. Heien, Lindsey R. Sangaralingham, et al.
Digestive Diseases and Sciences (2021) Vol. 67, Iss. 6, pp. 2510-2516
Open Access | Times Cited: 3
Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence
Joseph Meredith, Paul Henderson, David C. Wilson, et al.
Frontiers in Pediatrics (2021) Vol. 9
Open Access | Times Cited: 2
Therapie-Update Morbus Crohn 2021
Klaus Herrlinger, Eduard F. Stange
Gastro-News (2021) Vol. 8, Iss. 5, pp. 26-33
Closed Access | Times Cited: 2
Use of second Anti-Tumour Necrosis Factor Agent in Inflammatory Bowel Disease When First Agent Failed: A South African Retrospective Study
Ernst Fredericks, Abigail Titis, Suereta Fortuin, et al.
Archives of Pharmacology and Therapeutics (2022) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Predictive value of infliximab trough levels in maintenance therapy for 5-year sustained clinical remission in patients with inflammatory bowel disease
Yashar Jalali, Anna Gojdičová, Igor Šturdík, et al.
Bratislavské lekárske listy/Bratislava medical journal (2023) Vol. 124, Iss. 07, pp. 485-492
Open Access
Management of Inflammatory Bowel Disease: a long-term perspective
Remi Mahmoud
(2023)
Open Access

Scroll to top